CABANA Trial

BySteven Lome, MD

Summary: Evaluated catheter ablation versus antiarrhythmic drug therapy in patients with atrial fibrillation. The primary endpoint of freedom from atrial fibrillation was reduced with ablation (65%) versus antiarrhythmic drugs (41%). The trial is still enrolling with a goal of 3000 patients. The new primary endpoint is mortality with multiple secondary endpoints.

Original Publication:

None available. Results presented at national conferences.

https://www.cabanatrial.org/

Eponym: Catheter ABlation versus ANtiarrhythmic Drug Therapy for Atrial Fibrillation